Business Context and Reporting Period
This Form 8-K is a current report filed by Keros Therapeutics, Inc. on March 5, 2024. The filing serves as a Regulation FD disclosure regarding an upcoming corporate event rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document contains no financial statements or quantitative financial data.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely announces a scheduled presentation by company leadership.
Guidance, Outlook, and Management Commentary
Upcoming Event: Jasbir Seehra, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024, at 3:00 p.m. Eastern time.
Legal Disclaimer: The information in this report and the accompanying press release (Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the Leerink Partners 2024 Global Biopharma Conference presentation (March 12, 2024, 3:00 p.m. ET).
- Review the full text of the press release attached as Exhibit 99.1 for any additional details on the presentation topic.
- Confirm that no financial data is included in this specific 8-K filing; refer to the most recent 10-K or 10-Q for financial metrics.